Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330144 | 0.91 | MAPK14 (0.59) | MAPK14HSP90AA1 | |
| SCHEMBL4341309 | 0.88 | MAPK14 (0.77) | MAPK14HSP90AA1MEN1MAPK1KMT2A | |
| SCHEMBL4339559 | 0.84 | MAPK14 (0.67) | MAPK14HSP90AA1NOTUMMLYCD | |
| SCHEMBL4333445 | 0.84 | MAPK14 (0.59) | MAPK14MAPK1KMT2ANOTUMMLYCD | |
| SCHEMBL4335615 | 0.84 | MAPK14 (0.62) | MAPK14HSP90AA1MEN1MAPK1KMT2A | |
| SCHEMBL4334555 | 0.83 | MAPK14 (0.65) | MAPK14HSP90AA1PTGS2 | |
| SCHEMBL4347352 | 0.82 | MAPK14 (0.63) | MAPK14HSP90AA1MEN1MAPK1KMT2A | |
| SCHEMBL4335365 | 0.82 | MAPK14 (0.76) | MAPK14HSP90AA1PTGS2 | |
| SCHEMBL4340360 | 0.81 | MAPK14 (0.52) | MAPK14HSP90AA1MEN1MAPK1KMT2A | |
| SCHEMBL4470223 | 0.81 | MAPK14 (0.61) | MAPK14HSP90AA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885HSP90AA1 2550/4885MEN1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.